Molecular Diagnosis

, Volume 8, Issue 2, pp 93–100 | Cite as

Detection of MYCN amplification and chromosome 1p36 loss in neuroblastoma by cDNA microarray comparative genomic hybridization

  • Paola Scaruffi
  • Stefano Parodi
  • Katia Mazzocco
  • Raffaella Defferrari
  • Vincenzo Fontana
  • Stefano Bonassi
  • Gian Paolo ToniniEmail author
Original Research Article


Background: In the last decade, microarray technology has been extensively used to evaluate gene expression profiles and genome imbalances. We have developed a microarray-based comparative genomic hybridization (CGH) approach to identify MYCN gene amplification and 1p36 chromosome loss, two markers of tumor aggressiveness in neuroblastoma.

Aim: The aim was to use microarray CGH technology to detect the two major prognostic markers for neuroblastoma, MYCN amplification and 1p36 chromosome deletion, in neuroblastoma patients and, therefore, confirm the usefulness of this approach in this cancer.

Methods: DNA was purified from 16 tumors containing at least 90% malignant neuroblasts and collected at the onset of disease. Pooled fluorescent-labeled reference and neuroblastoma tumor genomic DNA was hybridized to epoxide-coated glass slides on laboratory-made complementary DNA microarray. The microarray contained cDNA mapped at the 1p36.33–36.1 chromosomal region and MYCN gene. cDNA from the 2q33–q34 and 12p13 chromosomes was used as a control and Arabidopsis thaliana DNA was spotted to control unspecific hybridization. Fluorescence in situ hybridization analysis was also performed to validate results from the microarray CGH.

Results: Both MYCN amplification and 1p36 chromosome deletion were detected by microarray CGH. The sensitivity and specificity for 1p36 loss detection were 66.7% and 90.0%, respectively. The method had a sensitivity of 66.7% and specificity of 90.9% to detect MYCN amplification.

Discussion: Our results demonstrated that the microarray CGH can be efficiently applied to study DNA gain and loss of specific chromosome regions.


Neuroblastoma Comparative Genomic Hybridization MYCN Amplification Neuroblastoma Patient MYCN Gene 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This work was supported by the Fondazione Italiana per la Lotta al Neuroblastoma, Associazione Italiana per la Ricerca sul Cancro (AIRC), European Union 5th FP (QLRT-2001-02831 and QLRT-2001-02198) and the Ministero dell’Università e della Ricerca Scientifica e Tecnologica. We are grateful to the surgeons, clinicians, and pathologists of the Italian Cooperative Group for Neuroblastoma and to the Associazione Italiana di Ematologia e Oncologia Pediatrica for providing tumor samples.

Dr Scaruffi was partially supported by a Research Training Fellowship awarded by the International Agency for Research on Cancer. The authors have provided no information on conflicts of interest directly relevant to the content of this study.


  1. 1.
    Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003; 3: 203–16PubMedCrossRefGoogle Scholar
  2. 2.
    Brodeur GM, Seeger RC, Schwab M, et al. Amplification of N-MYC in untreated human neuroblastomas correlates with advanced disease stage. Science 1984; 224: 1121–4PubMedCrossRefGoogle Scholar
  3. 3.
    Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985; 313: 1111–6PubMedCrossRefGoogle Scholar
  4. 4.
    White PS, Maris JM, Beltinger C, et al. A region of consistent deletion in neuroblastoma maps within human chromosome 1p36.2–36.3. Proc Natl Acad Sci U S A 1995; 92: 5520–4PubMedCrossRefGoogle Scholar
  5. 5.
    Caron H, van Sluis P, de Kraker J, et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med 1996; 334: 225–30PubMedCrossRefGoogle Scholar
  6. 6.
    Tonini GP, Boni L, Pession A, et al. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children. J Clin Oncol 1997; 15: 85–93PubMedGoogle Scholar
  7. 7.
    Ambros IM, Benard J, Boavida M, et al. Quality assessment of genetic markers used for therapy stratification. J Clin Oncol 2003; 21: 2077–84PubMedCrossRefGoogle Scholar
  8. 8.
    Veltman JA, Fridlyand J, Pejavar S, et al. Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors. Cancer Res 2003; 63: 2872–80PubMedGoogle Scholar
  9. 9.
    Bruder CE, Hirvela C, Tapia-Paez I, et al. High resolution deletion analysis of constitutional DNA from neurofibromatosis type 2 (NF2) patients using microarray-CGH. Hum Mol Genet 2001; 10: 271–82PubMedCrossRefGoogle Scholar
  10. 10.
    Hui AB, Lo KW, Yin XL, et al. Detection of multiple gene amplifications in glioblastoma multiforme using array-based comparative genomic hybridization. Lab Invest 2001; 81: 717–23PubMedCrossRefGoogle Scholar
  11. 11.
    Takeo S, Arai H, Kusano N, et al. Examination of oncogene amplification by genomic DNA microarray in hepatocellular carcinomas: comparison with comparative genomic hybridization analysis. Cancer Genet Cytogenet 2001; 130: 127–32PubMedCrossRefGoogle Scholar
  12. 12.
    Wilhelm M, Veltman JA, Olshen AB, et al. Array-based comparative genomic hybridization for the differential diagnosis of renal cell cancer. Cancer Res 2002; 62: 957–60PubMedGoogle Scholar
  13. 13.
    Clark J, Edwards S, John M, et al. Identification of amplified and expressed genes in breast cancer by comparative hybridization onto microarrays of randomly selected cDNA clones. Genes Chromosomes Cancer 2002; 34: 104–14PubMedCrossRefGoogle Scholar
  14. 14.
    Seo MY, Rha SY, Yang SH, et al. The pattern of gene copy number changes in bilateral breast cancer surveyed by cDNA microarray-based comparative genomic hybridization. Int J Mol Med 2004; 13: 17–24PubMedGoogle Scholar
  15. 15.
    Arai H, Ueno T, Tangoku A, et al. Detection of amplified oncogenes by genome DNA microarrays in human primary esophageal squamous cell carcinoma: comparison with conventional comparative genomic hybridization analysis. Cancer Genet Cytogenet 2003; 146: 16–21PubMedCrossRefGoogle Scholar
  16. 16.
    Clark J, Edwards S, Feber A, et al. Genome-wide screening for complete genetic loss in prostate cancer by comparative hybridization onto cDNA microarrays. Oncogene 2003; 22: 1247–52PubMedCrossRefGoogle Scholar
  17. 17.
    Wessendorf S, Schwaenen C, Kohlhammer H, et al. Hidden gene amplifications in aggressive B-cell non-Hodgkin lymphomas detected by microarray-based comparative genomic hybridization. Oncogene 2003; 22: 1425–9PubMedCrossRefGoogle Scholar
  18. 18.
    Squire JA, Pei J, Marrano P, et al. High-resolution mapping of amplifications and deletions in pediatric osteosarcoma by use of CGH analysis of cDNA microarrays. Genes Chromosomes Cancer 2003; 38: 215–25PubMedCrossRefGoogle Scholar
  19. 19.
    Tong CY, Hui AB, Yin XL, et al. Detection of oncogene amplifications in medulloblastomas by comparative genomic hybridization and array-based comparative genomic hybridization. J Neurosurg 2004; 100: 187–93PubMedGoogle Scholar
  20. 20.
    Schwaenen C, Nessling M, Wessendorf S, et al. Automated array-based genomic profiling in chronic lymphocytic leukemia: development of a clinical tool and discovery of recurrent genomic alterations. Proc Natl Acad Sci U S A 2004; 101: 1039–44PubMedCrossRefGoogle Scholar
  21. 21.
    Beheshti B, Braude I, Marrano P, et al. Chromosomal localization of DNA amplifications in neuroblastoma tumors using cDNA microarray comparative genomic hybridization. Neoplasia 2003; 5: 53–62PubMedGoogle Scholar
  22. 22.
    Ambros PF, Ambros IM, and the SIOP Europe Neuroblastoma Pathology, et al. Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines. Med Pediatr Oncol. 2001 Dec; 37(6): 492–504PubMedCrossRefGoogle Scholar
  23. 23.
    Shimada H, Ambros IM, Dehner LP, et al. The international neuroblastoma pathology classification (the Shimada system). Cancer 1999; 86: 364–72PubMedCrossRefGoogle Scholar
  24. 24.
    Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. New York: Cold Spring Harbor Laboratory Press, 1989Google Scholar
  25. 25.
    I.M.A.G.E. Consortium [online]. Available from URL: [Accessed 2004 Jul 28]
  26. 26.
    NCBI UniGene [online]. Available from URL: [Accessed 2004 July 20]
  27. 27.
    Lo Cunsolo C, Iolascon A, Cavazzana A, et al. Neuroblastoma in two siblings supports the role of 1p36 deletion in tumor development. Cancer Genet Cytogenet 1999; 109: 126–30PubMedCrossRefGoogle Scholar
  28. 28.
    Peter M, Michon J, Vielh P, et al. PCR assay for chromosome 1p deletion in small neuroblastoma samples. Int J Cancer 1992; 52: 544–8PubMedCrossRefGoogle Scholar
  29. 29.
    Schena M. Microarray analysis. New York: J Wiley & Sons Press, 2003Google Scholar
  30. 30.
    Nadon R, Shoemaker J. Statistical issues with microarrays: processing and analysis. Trends Genet 2002; 18: 265–71PubMedCrossRefGoogle Scholar
  31. 31.
    Shoemaker DD, Linsley PS. Recent developments in DNA microarrays. Curr Opin Microbiol 2002; 5: 334–7PubMedCrossRefGoogle Scholar
  32. 32.
    Ambros PF, Ambros IM, Kerbl R, et al. Intratumoural heterogeneity of 1p deletions and MYCN amplification in neuroblastomas. Med Pediatr Oncol 2001; 36: 1–4PubMedCrossRefGoogle Scholar
  33. 33.
    Takeda O, Homma C, Maseki N, et al. There may be two tumor suppressor genes on chromosome arm 1p closely associated with biologically distinct subtypes of neuroblastoma. Genes Chromosomes Cancer 1994; 10: 30–9PubMedCrossRefGoogle Scholar
  34. 34.
    Iolascon A, Lo Cunsolo C, Giordani L, et al. Interstitial and large chromosome 1p deletion occurs in localized and disseminated neuroblastomas and predicts an unfavorable outcome. Cancer Lett 1998; 130: 83–92PubMedCrossRefGoogle Scholar
  35. 35.
    Solinas-Toldo S, Lampel S, Stilgenbauer S, et al. Matrix-based comparative genomic hybridization: biochips to screen for genomic imbalances. Genes Chromosomes Cancer 1997; 20: 399–407PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  • Paola Scaruffi
    • 1
    • 2
  • Stefano Parodi
    • 3
  • Katia Mazzocco
    • 2
  • Raffaella Defferrari
    • 2
  • Vincenzo Fontana
    • 3
  • Stefano Bonassi
    • 3
  • Gian Paolo Tonini
    • 1
    Email author
  1. 1.Laboratory of NeuroblastomaNational Cancer Research Institute (IST)GenoaItaly
  2. 2.Italian Neuroblastoma FoundationAdvanced Biotechnology CenterGenoaItaly
  3. 3.Environmental Epidemiology and BiostatisticsNational Cancer Research Institute (IST)GenoaItaly

Personalised recommendations